Study Comparing Short Prasugrel-Based Dual Antiplatelet Therapy Followed by Prasugrel Alone Versus Standard Dual Antiplatelet Therapy in Heart Attack Patients with OCT- or Angio-Guided Complete Revascularization
Led by Research Maatschap Cardiologen Rotterdam Zuid · Updated on 2026-07-02
1656
Participants Needed
27
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
This research focuses on patients who have experienced ST segment elevation myocardial infarction STEMI and require percutaneous coronary intervention PCI. The study compares two approaches a shorter duration of dual antiplatelet therapy DAPT with Prasugrel followed by Prasugrel monotherapy versus the standard one-year DAPT regimen. Additionally, in patients with multivessel disease MVD, the trial evaluates the effectiveness and safety of complete revascularization guided by either Optical Coherence Tomography OCT or angiography.
Participants receive a loading dose of aspirin and Prasugrel at the time of PCI, treating the culprit lesion first. For those with MVD, non-culprit lesions are treated in staged procedures within 15 days. Following 30 to 45 days after the initial procedure, eligible patients are randomized to either continue short DAPT with Prasugrel monotherapy or follow the standard 12-month DAPT. Complete revascularization in MVD patients is further randomized to OCT-guided or angiography-guided strategies.
Participants will be followed clinically for 35 months after randomization to monitor outcomes, with key assessments at 11 and 35 months. Researchers will measure safety and efficacy endpoints, including major adverse cardiac and cerebrovascular events and bleeding events. The study includes detailed monitoring of treatment adherence, successful revascularization, and clinical events to evaluate the comparative benefits of the treatment strategies.
CONDITIONS
Brief Title
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
Research Team
V
Valeria Paradies, MD
R
Ria van Vliet
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Adults with ST segment elevation myocardial infarction (STEMI) planned for PCI
Chest discomfort suggestive of cardiac ischemia lasting 20 minutes or more at rest
ECG showing ST segment elevation in 2 or more contiguous leads or new/presumed new left bundle branch block
For multivessel disease, treatment of culprit lesion during primary PCI recommended
Provided informed consent
Compliance with DAPT with no changes in regimen
No major adverse events such as MI, stroke, stent thrombosis, or major bleeding
Successful revascularization with less than 30% residual stenosis
Complete revascularization of non-culprit lesions within 15 days if multiple significant lesions
You will not qualify if you...
Use of oral anticoagulants
Allergy or contraindication to P2Y12 inhibitors, aspirin, or related substances
Prior use of P2Y12 inhibitors other than Prasugrel before admission
Use of strong CYP3A inhibitors, substrates, or inducers that affect Prasugrel
Platelet count below 100,000/µL
Anemia with hemoglobin below 10 g/dL
Comorbidities with life expectancy less than 1 year
Pregnancy, recent childbirth within 90 days, or breastfeeding
History of stent thrombosis or indication for stent thrombosis PCI
Urgent major surgery planned after PCI
Cardiogenic shock or out-of-hospital cardiac arrest without prompt return of circulation
Severe renal impairment with creatinine clearance 30 ml/min/1.73 m2 or less
Participation in another interventional trial within the last 12 months or recent investigational drug use
Lack of informed consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Initial PCI and Loading Dose
Duration - Up to 15 days
Participants receive aspirin and Prasugrel loading dose, and the culprit lesion is treated during the initial procedure. Non-culprit lesions in multivessel disease are treated in staged procedures within 15 days.
Randomization and Treatment
Duration - 11 months to 1 year
At 30 to 45 days after the initial procedure, eligible patients are randomized to either Prasugrel monotherapy after short DAPT or standard 12-month DAPT regimen. Patients with multivessel disease are randomized to either OCT-guided or angiography-guided revascularization strategies.
Regular follow-up visits
Long-term Follow-up
Duration - Up to 35 months
Participants are followed for clinical outcomes to assess safety and efficacy, with key assessments at 11 and 35 months after randomization.
Periodic clinical visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Comparing 24-Month Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent Placement in Patients With High Lipoproteina Levels
Study Comparing Short Prasugrel-Based Dual Antiplatelet Therapy Followed by Prasugrel Alone Versus Standard Dual Antiplatelet Therapy in Heart Attack Patients with OCT- or Angio-Guided Complete Revascularization
Study of 1-Year Dual Antiplatelet Therapy After GENOSS Sirolimus Eluting Stent for Coronary Artery Disease in High-Risk Patients
Study on Safety and Effectiveness of Short-Term Dual Antiplatelet Therapy After GENOSS DES Stent Placement in Coronary Artery Disease Patients
Study of Rituximab 1000 mg Versus Placebo to Improve Heart Function After ST-Elevation Myocardial Infarction STEMI
Study Comparing Single and Dual Antiplatelet Therapy in Older or High Bleeding Risk Patients Undergoing Coronary Intervention with Drug-Coated Balloons
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Prasugrel monotherapy versus standard DAPT in STEMI patients with OCT-guided or angio-guided complete revascularisation: design and rationale of the randomised, multifactorial COMPARE STEMI ONE trial.
Valeria Paradies, Nicolas M Van Mieghem, Rohit M Oemrawsingh...